Percutaneous hepatic perfusion improves response rates and progression-free survival in metastatic uveal melanoma
Liver perfusion shows better response rates for metastatic uveal melanoma
This meta-analysis of patients with metastatic uveal melanoma found that percutaneous hepatic perfusion (PHP) is associated with higher over…
A new analysis suggests liver perfusion may improve response and progression-free time for patients with a rare form of eye cancer.
Germline BAP1 variants are associated with aggressive clinical phenotypes in patients with uveal melanoma
Genetic variants linked to more aggressive eye cancer cases
This systematic review examines the clinical phenotype of uveal melanoma in patients harboring germline pathogenic or likely pathogenic BAP1…
A specific genetic marker, BAP1, is linked to earlier diagnoses and higher risks of spreading in certain types of eye cancer.
Tebentafusp provides modest survival benefit and manageable safety profile in metastatic uveal melanoma
Trial Shows Tebentafusp Offers Survival Benefit for Metastatic Uveal Melanoma
This systematic review and meta-analysis of 631 patients evaluates tebentafusp for metastatic uveal melanoma. The analysis found an overall …
Tebentafusp shows a modest survival benefit for patients with metastatic uveal melanoma, despite low response rates and manageable side effe…
Network meta-analysis compares therapies for liver metastatic uveal melanoma
Liver-directed therapy combined with ICIs leads for metastatic uveal melanoma survival
This systematic review and network meta-analysis synthesized evidence on therapeutic modalities for patients with liver metastatic uveal mel…
A network meta-analysis of 2,585 patients found liver-directed therapy combined with immune checkpoint inhibitors offered the best survival …
Combined tebentafusp and SBRT showed disease control in a patient with metastatic uveal melanoma
One Woman’s Rare Eye Cancer Spread. Then a New Combo Stopped It Cold
This case report describes a 39-year-old woman with localized uveal melanoma who developed liver and hilar adenopathy metastases.
This story shows how combining a new immune drug with targeted radiation may help the body fight cancer longer, even after it has spread.
Immunoembolization shows lower disease control than FOCUS trial in liver-dominant metastatic uveal melanoma
Eye Cancer in Liver: New Therapy Extends Life Even When Tumors Grow
This single-center retrospective analysis evaluated immunoembolization (IE) in 43 patients with liver-dominant metastatic uveal melanoma.
A new liver treatment for eye cancer patients may help them live longer, even if it does not shrink tumors as much as expected.
Phase II trial compares IMCgp100 vs investigator choice in advanced uveal melanoma
Can a new drug help people with a rare eye cancer live longer?
This Phase II study evaluated IMCgp100 versus investigator's choice (dacarbazine, ipilimumab, or pembrolizumab) in HLA-A*0201 positive adult…
A new drug for advanced eye cancer is being compared to standard treatments to see if it helps patients with a specific genetic marker live …
Research across Melanoma
Related studies from across the Melanoma family.
Encorafenib and Binimetinib Combination Therapy for Patients with BRAF Mutated Cutaneous Melanoma
Trial Shows Encorafenib and Binimetinib for Melanoma Patients
This trial evaluates the safety and efficacy of encorafenib and binimetinib in patients with resected stage IIB/IIC melanoma.
A clinical trial shows that a combination of encorafenib and binimetinib may improve recurrence-free survival for patients with specific mel…
Objective response rate correlates with overall survival in nivolumab-containing regimens for metastatic melanoma
Nivolumab regimens show link between tumor shrinkage and melanoma survival
This meta-analysis of 1865 treatment-naive patients with metastatic melanoma evaluated the association between clinical surrogates and overa…
New data shows that shrinking tumors and staying stable provides a strong link to longer survival for patients with metastatic melanoma.
Mitophagy acts as a core barrier to effective immunotherapy in melanoma and other skin cancers
Mitophagy acts as a barrier to skin cancer immunotherapy
This narrative review explores how mitophagy functions as a barrier to immunotherapy in melanoma, cutaneous squamous cell carcinoma, and bas…
A cellular process called mitophagy may help skin cancers hide from the immune system, making it harder for certain treatments to work.
PGE2 signaling via EP receptors drives tumor progression and context-dependent neuroinflammation in various diseases
Understanding the Role of PGE2 Signaling in Brain Health and Cancer
This systematic review examines the role of PGE2 signaling across neurological, oncological, and metabolic conditions. The findings indicate…
New research shows how different parts of a single protein pathway can either protect your brain or help tumors grow.
mRNA vaccines offer a flexible and rapid production platform for personalized melanoma immunotherapy
mRNA Vaccines Show Promise for Treating Melanoma Cancer
This systematic review examines mRNA cancer vaccines, including lipid nanoparticle delivery systems, as potential treatments for melanoma. T…
New research highlights mRNA technology as a flexible and fast way to develop personalized treatments for melanoma patients.
Fecal microbiota transplantation may modulate tumor microenvironment and enhance immunotherapy responses in several cancers
Fecal Microbiota Transplantation Shows Potential for Several Cancer Treatments
This systematic review explores the role of fecal microbiota transplantation (FMT) in treating colorectal cancer, liver cancer, and melanoma…
Fecal microbiota transplantation may help manage side effects and improve how the body responds to cancer treatments like chemotherapy and i…
Pregnancy-associated melanoma does not independently worsen overall survival when stage is adequately controlled
Pregnancy associated melanoma does not lower overall survival rates
This meta-analysis of observational studies involving 16,467 women found no significant difference in overall survival for patients with pre…
New data shows that a melanoma diagnosis during or shortly after pregnancy does not change the long-term survival outlook for women.
CD73-adenosine axis serves as a metabolic immune checkpoint and potential target to overcome melanoma resistance
CD73 Target May Help Overcome Melanoma Treatment Resistance
This systematic review examines the role of the CD73-adenosine axis in advanced melanoma and its implications for treatment resistance. The …
New research explores how blocking the CD73-adenosine axis could help patients with advanced melanoma overcome resistance to current treatme…
AI-assisted clinicians achieve 1.000 sensitivity in melanoma diagnosis but autonomous AI lacks clear clinical advantage
Artificial Intelligence Shows Mixed Results in Detecting Melanoma
This meta-analysis of 17 diagnostic arms from 10 studies evaluates artificial intelligence for dermoscopic image analysis in melanoma detect…
New research shows that while AI can help identify skin cancer, it does not yet outperform traditional methods used by doctors.
Opsin 3 serves as a potential therapeutic target for melanoma and inflammatory skin diseases
Opsin 3 May Offer New Path for Skin Disease Treatment
This narrative review explores the role of Opsin 3 (OPN3) in skin pathophysiology, including its involvement in UV damage, melanoma developm…
A protein called Opsin 3 may play a key role in how skin cells respond to UV damage, aging, and inflammation.
AI diagnostic tools show high accuracy but limited real-world validation in systematic review
Artificial intelligence shows high accuracy in detecting various medical conditions
This systematic review of 24 studies synthesizes evidence on AI and deep learning for disease detection across multiple imaging modalities. …
New analysis of 24 studies shows AI tools can reach over 90% accuracy in spotting everything from lung cancer to skin disorders.
Actinic keratosis increases melanoma risk while alcohol consumption is associated with lower squamous cell carcinoma risk
Actinic Keratosis Linked to Higher Risk of Melanoma
This meta-analysis of genome-wide association studies evaluates causal relationships between 11 modifiable risk factors and skin cancers. Th…
New research identifies a link between actinic keratosis and melanoma risk while highlighting potential new targets for skin cancer treatmen…
Questions about Uveal Melanoma
Did a patient with uveal melanoma benefit from combined tebentafusp and SBRT?
Yes, a case report describes a patient with metastatic uveal melanoma who achieved durable disease control after adding SBRT to tebentafusp, with a partial response and 35 months of maintained control.
Full answer →What treatments are available for liver metastatic uveal melanoma patients?
Liver-directed therapy combined with immune checkpoint inhibitors appears most effective; tebentafusp is approved for HLA-A*02:01+ patients; other options include immunoembolization, SBRT, and clinical trials.
Full answer →How does immunoembolization compare to the FOCUS trial for uveal melanoma?
Immunoembolization shows lower disease control rates than the FOCUS trial for liver-dominant metastatic uveal melanoma, though tebentafusp combined with radiotherapy may offer durable control in specific cases.
Full answer →Can tebentafusp and SBRT control disease in uveal melanoma?
Yes, a case report shows tebentafusp plus SBRT controlled metastatic uveal melanoma for over 35 months, but more research is needed to confirm this approach.
Full answer →